Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206024 · ClinicalTrials.gov registry record · Phase 4
Acid-Associated Heartburn Symptoms and Dose of Esomeprazole
A Phase 4 study of Heartburn, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT00206024: Completed Phase 4 study of Heartburn, sponsored by AstraZeneca.
NCT00206024 is a Phase 4 study of Heartburn that has completed, run by AstraZeneca. The registered enrollment target is 330 participants, below the 383-participant average among 9 other Heartburn trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206024, a Phase 4 study of Heartburn, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, double-blind, parallel-group, randomized, proof of concept trial to investigate the relationship between dose of esomeprazole magnesium and acid-associated heartburn symptoms during 4 weeks of treatment. The safety and tolerability of esomeprazole magnesium in doses up to 40 mg BID will also be assessed.
Conditions Studied
Interventions
- DRUG Esomeprazole magnesium (Nexium)
Study Locations (20)
Florida
- Research Site - DeLand
- Research Site - Miami
- Research Site - New Smyrna Beach
- Research Site - Tampa
- Research Site - Zephyrhills
California
- Research Site - Anaheim
- Research Site - Orange
- Research Site - San Diego
Maryland
- Research Site - Annapolis
- Research Site - Baltimore
- Research Site - Hollywood
New Jersey
- Research Site - Hackensack
- Research Site - Vineland
Arizona
- Research Site - Tucson
District of Columbia
- Research Site - Washington D.C.
Georgia
- Research Site - Atlanta
Illinois
- Research Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2004-11 |
| Est. Completion | 2005-07 |
| Phase | Phase 4 |
What the finished NCT00206024 record still lists
NCT00206024 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, below the 383-participant average among 9 other Heartburn trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Heartburn appearing as the primary indexed condition, and to 1 intervention - of which Esomeprazole magnesium (Nexium) is the first listed.
NCT00206024 names 20 study sites across 11 states, led by Florida, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT00206024 about?
NCT00206024 is a clinical study titled "Acid-Associated Heartburn Symptoms and Dose of Esomeprazole". This is a multi-center, double-blind, parallel-group, randomized, proof of concept trial to investigate the relationship between dose of esomeprazole magnesium and acid-associated heartburn symptoms during 4 weeks of treatment. The safety and tolerability of esomeprazole magnesium in doses up to 40 ...
What is the current status of trial NCT00206024?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 330 participants. The study started on 2004-11. Estimated completion is 2005-07.
What conditions does trial NCT00206024 study?
This clinical trial studies the following conditions: Heartburn.
What interventions are being tested in trial NCT00206024?
The interventions under investigation include: Esomeprazole magnesium (Nexium) (DRUG).
Who is sponsoring clinical trial NCT00206024?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00206024 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heartburn
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00206024's enrollment target sits among peer trials
330 6th of 9 higher than 4 of 9 other Heartburn trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heartburn trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
-
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
RECRUITING
-
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
COMPLETED · Phase 3
-
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
COMPLETED · Phase 3
-
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia